Actuate Therapeutics to Showcase Innovations at Key Conference
![Actuate Therapeutics to Showcase Innovations at Key Conference](https://investorshangout.com/images/blog/ihnews-Actuate%20Therapeutics%20to%20Showcase%20Innovations%20at%20Key%20Conference.jpg)
Actuate Therapeutics to Present at a Leading Investment Conference
Actuate Therapeutics, Inc. (NASDAQ: ACTU), known for its innovative approaches in battling challenging cancers, is gearing up to make a significant impact at a prominent investment conference. This clinical-stage biopharmaceutical company specializes in developing therapies targeting difficult-to-treat malignancies, including pancreatic cancer and Ewing sarcoma, driven by the inhibition of glycogen synthase kinase-3 beta (GSK-3?).
Conference Details
Taking place from September 9 to 11, 2024, the H.C. Wainwright 26th Annual Global Investment Conference in New York City will be the venue for Actuate’s presentation. The company plans to showcase its advancements and strategies aimed at therapeutic solutions for high-impact cancers. In addition to the presentation, the management team will be open for one-on-one meetings, allowing investors and stakeholders to engage directly.
Presentation Format and Schedule
The presentation by Actuate Therapeutics will follow a corporate format, perfectly designed to capture the attention of investors and industry leaders alike. On September 10, 2024, at 4:00 PM ET, the company will share insights into its innovative approaches and the science behind its lead product, elraglusib.
Webcast Availability
For those who cannot attend in person, the presentation will also be live-streamed. Following the event, a recorded version will be available, allowing stakeholders to catch up on the latest developments from Actuate Therapeutics.
Overview of Actuate Therapeutics
Actuate is committed to pioneering therapies that stand a chance against aggressive cancer types. Their lead investigational product, elraglusib, is at the forefront of this effort. It operates as a GSK-3 inhibitor, targeting various molecular pathways that contribute to tumor growth and chemoresistance. Elraglusib aims to enhance anti-tumor immunity by inhibiting NF-kB while also managing immune checkpoints and cell functions.
Investor Relations and Contact Information
For those interested in learning more about Actuate or engaging with the company, Mike Moyer serves as the Managing Director at LifeSci Advisors, LLC. You can reach out to him directly via email for inquiries related to investments and company details.
Frequently Asked Questions
What is the focus of Actuate Therapeutics?
Actuate Therapeutics is focused on developing therapies for high-impact, difficult-to-treat cancers, particularly pancreatic cancer and Ewing sarcoma.
When will Actuate present at the H.C. Wainwright Conference?
Actuate is scheduled to present on September 10, 2024, at 4:00 PM ET during the conference.
How can I access the webcast of Actuate's presentation?
The presentation will be available via webcast, with a recorded version accessible after the live presentation.
What is elraglusib?
Elraglusib is Actuate's lead investigational drug that targets GSK-3, aiming to diminish tumor growth and enhance immune response.
Who can I contact for investor inquiries regarding Actuate?
For investor-related questions, you can contact Mike Moyer at LifeSci Advisors, LLC.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- EUR/USD Stability as Market Awaits Key US Employment Figures
- Navigating the Coming Interest Rate Cuts: Strategies for You
- Morning Market Memo: Key Insights on Major Stocks
- Market Watch: Stocks React to Labor Data and Earnings Reports
- Analyzing Short Interest Trends in Sherwin-Williams Stock
- Understanding Rivian Automotive's Latest Short Interest Trends
- The Impact of Investing in Burlington Stores Over a Decade
- Unical Aviation Expands Services with ecube Solutions Acquisition
- Kanzhun's Struggles Highlight Market Dynamics and Investor Sentiment
- Lindahl Reed Expands Operations with New Washington Office
Recent Articles
- EUR/USD Stability as Market Awaits Key US Employment Figures
- Navigating the Coming Interest Rate Cuts: Strategies for You
- Morning Market Memo: Key Insights on Major Stocks
- Market Watch: Stocks React to Labor Data and Earnings Reports
- Analyzing Short Interest Trends in Sherwin-Williams Stock
- Understanding Rivian Automotive's Latest Short Interest Trends
- Understanding Old Dominion Freight Line's Short Interest Trends
- The Impact of Investing in Burlington Stores Over a Decade
- Investment Growth of Commercial Metals Over 5 Years
- Unical Aviation Expands Services with ecube Solutions Acquisition
- Kanzhun's Struggles Highlight Market Dynamics and Investor Sentiment
- A-G Specialty Insurance Enhances Capabilities with New Acquisition
- Lindahl Reed Expands Operations with New Washington Office
- FuelCell Energy Reports Solid Q3 Results with Revenue Growth
- Revolutionary AISPEECH M6 Speakerphone Transforms Meetings
- Commemorating the First Continental Congress with New Stamps
- Discover Infantino's Adorable My 1st Tumbler for Kids
- Dierks Bentley Launches ROW 94 Whiskey with Unique Craftsmanship
- Eagle Protect Highlights Glove Safety Amid Food Recall Rise
- Mesirow Wealth Advisors Recognized as Top Next-Gen Financial Experts
- SolarPanelRecycling.com Earns Accreditation from SEIA
- Agora Unveils Innovative Tools to Transform Real Estate Investing
- Eco Material Technologies' 2023 Report: A Green Revolution in Cement
- BizClik Media Unveils New Editions of Sustainability & EV Magazines
- Enhancing Experiences: Scheerer Bearing's New Digital Catalog
- 2025 Ram 1500's Hurricane Engine Named Among Top Best Engines
- Zencoder Shines at TechCrunch Disrupt 2024 Startup Battlefield
- Manifest Partners with Department of Defense on SBOM Solutions
- Challenges Ahead for Michel Barnier as New Prime Minister
- Relief Bed Partners to Enhance Sleep for Orphans in Africa
- Navigating Political Challenges: Macron's Strategy with Barnier
- Legal Action Against Snapchat for Child Safety Concerns
- Seven & i Board Responds to Couche-Tard's Initial Offer
- Athens Stock Market Sees Positive Growth With Key Sectors Rising
- Understanding the Recent Performance of Israeli Stocks
- Market Overview: Norway's Stocks Decline with Key Movers
- Samson Mow's Bitcoin Predictions: An Omega Candle Ahead?
- Gold Market Shakes as Miners Experience Major Decline
- S&P 500 Forecast: Navigating Market Uncertainty Ahead
- FuelCell Energy's Q3 Performance: Insights and Future Prospects
- Empowering Futures: Tallo Joins Forces with SC Future Makers
- TRIMEDX Earns Spot in 2024 Inspiring Workplaces Rankings
- Intesa Sanpaolo Achieves Top Rankings for Leadership and ESG
- Passenger Preferences Unveiled: Convenience in Coastal Travel
- Harnessing AI for Enhanced Supply Chain Analytics in 2024
- Underwater Welding Equipment Market: Growth Insights and Trends
- Returnable Packaging Sector Projected to Nearly Double by 2033
- Automotive Diagnostic Scan Tool Market Forecast for 2034
- The Astaxanthin Market's Bright Future and Growth Factors
- Exploring the Robust Growth of Non-Alcoholic Drinks Market